Asset profile
MK-2214
Monoclonal antibody
Evidence outlook · lead readout
NCT05466422 · Alzheimer Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05466422: Participants were randomly assigned to MK-2214 or placebo under double-blind conditions, a sound design for an early-phase study, but the primary measures were safety events and a cerebrospinal-fluid biomarker rather than a clinical outcome, and results have not yet been reported.
The published report does not name this study's registry identifier; the match rests on the study design and the participant count.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2029 (1)
April 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.